-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Reiterates Outperform on Contineum Therapeutics, Maintains $31 Price Target

Benzinga·05/15/2025 16:20:57
Listen to the news
RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and maintains $31 price target.